USING SYNTHESISED ORGANIC COMPOUNDS AS ENVIRONMENTALLY FRIENDLY RETARDANTS FOR ORNAMENTAL PLANTS
The pre-sowing treatment of scarlet sage (Salvia splendens Ker Gawl.) seeds with 4-methyl-2-piperidin1-yl-pyrimidine-5-carboxylic acid at concentrations of 0.01, 0.05, and 0.1% proved to have an obvious inhibiting effect. Prior to sowing, the seeds of Salvia splendens were soaked in a water suspension of 4-methyl-2-piperidin-1-yl-pyrimidine-5-carboxylic acid and 4-methyl-2-morpholin-4-pyrimidine-5-carboxylic acid with concentrations of 0.01%, 0.05%, and 0.1% for 18 hours. On the 42nd day of the experiment, the seedlings, having been preliminarily hardened for 12 days, were removed from the greenhouse and planted on the field. The pre-sowing treatment of Salvia splendens seeds with 4-methyl-2-morpholin-4-pyrimidine-5-carboxylic acid proved to have the inhibiting effect at concentrations of 0.01 and 0.05%. The height of the seedlings decreased by 13.3-43.7%. It was revealed that 4-methyl-2-piperidin-1-yl-pyrimidine-5-carboxylic acid at concentrations of 0.01, 0.05, and 0.1% decreased the growth of the seedlings by 30.4-43.7%, and 4-methyl-2-morpholin-4-pyrimidine-5-carboxylic acid at concentrations of 0.01 and 0.05% decreased the growth of the seedlings by13.3-22.2%. By contrast, the effect of pyrimidinecarboxylic acids on seed germination and plant height of another annual flower – spreading marigold (Tagetes patula L.) was stimulating. It was investigated some different concentrations from 0.01 to 0.05 %. The same concentrations of identical compounds were tested, but effects from them were opposite for Tagetes patula, and Salvia splendens seedlings. Сonsequently, the species-specific effect of pyrimidinecarboxylic acids on seed germination and plant height for ornamental grasses takes place. Therefore,4-methyl-2-piperidin-1-yl-pyrimidine-5-carboxylic acid and 4-methyl-2-morpholin4-pyrimidine-5-carboxylic acid are recommended as growth retardants for Salvia splendens.
Read ArticleUNRAVELING THE COMPLEXITIES OF CARDIOVASCULAR MEDICINE: A CONVERSATION WITH DR. PETER MCCULLOUGH (EXTENDED EN-US VERSION)
Background: This interview covers Dr. Peter McCullough’s medical career, experience as an editor of medical journals, and his expertise in areas such as cardiomyopathy, myocarditis, and pericarditis. Aims: The primary aim is to understand Dr. McCullough’s perspectives on various medical topics, including his journey as a cardiologist, the importance of peer review, the phenomenon of Pheidippides cardiomyopathy, the differences between myocarditis and pericarditis, and the significance of ethical principles like the Nuremberg Code and the Declaration of Helsinki. Additionally, the interview aims to explore his concerns about censorship during the COVID-19 pandemic. Methods: The interview follows a question-and-answer format, with the interviewer posing questions to Dr. McCullough on various topics related to his medical career, research interests, and ethical considerations. Results: Dr. McCullough shares his insights on topics such as cardiomyopathy, myocarditis, and pericarditis, emphasizing the importance of peer review, identifying potential biases, and balancing scientific rigor with timely dissemination of findings. He also highlights the significance of the Nuremberg Code and the Declaration of Helsinki in ensuring informed consent and preventing coercion in medical research and treatment. Discussion: Dr. McCullough expresses concerns about censorship during the COVID-19 pandemic, which he believes impacted the ability of medical professionals to freely discuss and disseminate health-related information. He also discusses the potential role of COVID-19 vaccines in causing myocarditis and the need for transparent communication about treatment options and potential complications. Conclusion: The interview provides valuable insights from Dr. McCullough’s extensive medical experience and expertise, covering a range of topics from cardiovascular conditions to ethical principles and the challenges posed by censorship during the COVID-19 pandemic.
Read ArticleADVANCES IN NATURAL EXTRACTS USED FOR ANTIBIOTIC-RESISTANT BACTERIA TREATMENT: THE GRAM-NEGATIVE CASES
Background: Infectious diseases are a global problem, the second human cause of death. Infectious diseases caused by pathogenic bacteria have been treated with a high degree of efficacy. However, even when the 20th century was considered the “golden age” of antibiotics, bacteria developed a different resistance mechanism to antibiotics. In 2017, the WHO issued an alert about 12 bacteria with an urgent need to develop new antibiotics. Aims: The aim of the present review is to analyze the current knowledge of the antibacterial activity of natural extract-based treatments against the pathogens listed by WHO. Methods: A systematic review of the literature in PubMed was performed to search for publications describing the use of natural extracts as antibiotics over bacteria. We focused on the Gram-Negative group. The exclusion criteria consisted of limiting papers on natural extracts tested over the bacteria culture related to eight selected bacteria, according to an alert issued by WHO in 2017, and seven plant extracts. Results: All the Gram-Negative bacteria listed in 2017 by WHO have been treated, with different degrees of advance, with some of the plant extracts and plant-based compounds reviewed. In general, the first approach is using inhibition disks applied over the bacterial biofilm in solid culture media. Discussion: While Salmonellae and P. aeruginosa have been extensively studied, over N. gonorrhoeae, A. baumannii have been tested with fewer natural extracts. Edible herbs are more often used, as well as artemisa and wine byproducts. In all cases, they are in the early stages of study, not being tested in patients at present. Conclusions: Plant extracts and plant-based compounds are effective as antibacterial, with minimal effects on the host cell. Furthermore, they are sustainable, environmentally friendly, and renewable.
Read Article